Sheba Pediatric CAR-T Program for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) at JCI accreditated and Top-10 Hospitals 2025 by Newsweek Hospital
このパッケージに含まれるもの
医療処置
- CAR-T細胞療法
- 栄養士による1日3食
- 24時間看護サービス
- 心電図(ECG)
- 血液検査
- 胸部X線
- HIV抗体検査
- B型肝炎コア抗体検査
- 抗HCV抗体検査
- 心エコー図検査
- 生化学血液検査
- 腫瘍専門医との診察
- 血液専門医へのコンサルテーション
- 免疫専門医への相談
- 循環器科医への相談
- 小児血液専門医との相談
- 小児科医との相談
- 腫瘍血液専門医との診察
- 頭部MRI
- 生検
期間
- 21 日 病院で
宿泊
入院
交通
空港-クリニック-空港間の送迎
追加情報
Sheba Pediatric CAR-T Program for Non-Hodgkin Lymphomas (DLBCL, FL, MCL)
At Sheba Medical Center, children and young patients with Non-Hodgkin lymphomas have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program focuses on treating diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL), especially in relapsed or treatment-resistant cases using highly personalized immunotherapy.
A Personalized Treatment Designed for Each Child
CAR-T therapy uses the patient’s own immune system to identify and destroy cancer cells. This approach offers new hope for children and young patients when standard therapies are no longer effective.
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality:
Apheresis – collection of the patient’s T-cells
Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
Infusion – reintroduction of modified cells to target lymphoma
Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body over time and offering the potential for long-term remission.
Expert Pediatric Leadership and Care
The pediatric CAR-T program is led by Prof. Amos Toren, one of the most experienced specialists in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed.
The program includes:
Dedicated pediatric CAR-T units with 24/7 expert monitoring
A multidisciplinary team of hemato-oncologists, immunologists, and pediatric specialists
A supportive, family-centered environment designed for children
Full international patient support, including travel and care coordination
Proven Outcomes and Global Expertise
Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes:
~90% remission in pediatric patients
~80% in young adults (up to 23 years)
~70% in adults
The program is highly experienced in treating complex and high-risk lymphoma cases, offering advanced options when other treatments have been exhausted.
Comprehensive Evaluation and Support
Each child undergoes a thorough diagnostic evaluation, including:
advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment.
Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed at every stage.
A Trusted Place for Advanced Pediatric Cancer Care
By combining cutting-edge science, rapid access to treatment, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Non-Hodgkin lymphomas with CAR-T therapy focused on achieving remission and helping children return to a healthy, active life.
24時間年中無休Bookimedサポート
- 専任医療コーディネーター
- 医療旅行手配 — 特別パートナー価格での航空券・ホテル予約
- 医療旅行中の患者擁護
プログラム料金
このパッケージに含まれないもの
医師
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
調子はいかがですか?
クリニックについて
シェバ医療センターはイスラエルおよび世界有数の病院の一つです。 ニューズウィーク・インターナショナル誌は、Sheba Hospitalを2020年の世界トップ10病院にランク付けしました。同病院は1,990の専門分野をカバーしており、毎年世界中から1,500,000人を超える患者がシェバ病院を受診しています。
支払い・特典
当社サービスへのお支払いはありません
クリニックで直接またはその公式銀行口座にお支払いいただきます。
一部のクリニックでは保証金が必要な場合があります。
分割払いオプションでお支払いを分散してください。
Bookimedにお友達を紹介して報酬を獲得してください。